The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile
ABL 开关控制抑制剂 DCC-2036 可有效对抗慢性粒细胞白血病突变体 BCR-ABLT315I，并且具有较窄的耐药性
期刊:Cancer Research
影响因子:12.5
doi:10.1158/0008-5472.CAN-10-3224
Christopher A Eide, Lauren T Adrian, Jeffrey W Tyner, Mary Mac Partlin, David J Anderson, Scott C Wise, Bryan D Smith, Peter A Petillo, Daniel L Flynn, Michael W N Deininger, Thomas O'Hare, Brian J Druker
